Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2025 and reviewed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results